DENVER, Colorado — November 16, 2020 —Theralink Technologies (OTC: OBMP) (“Theralink” or the
“Company”), a precision oncology molecular profiling company with a novel phosphoprotein-based
laboratory developed test (LDT), today announced its partnership with Perthera, a market leader in
Precision Oncology technology and services. The alliance will facilitate and accelerate access to Theralink’s
32 phosphoprotein panel, the Theralink assay, across the U.S. for breast cancer patients.
Theralink will be launching its Reverse Phase Protein Array (RPPA) based LDT this year. This unique assay
is the world’s only phosphoprotein panel LDT that directly measures the activation state of targets of over
100 precision therapeutics at once. Together, Theralink and Perthera will collaborate to provide the
Theralink assay results to oncologists in an easy to interpret, “powered by Perthera” report for potentially
improved insights into therapeutic options for the patient’s care plan.
Through this partnership, Perthera will develop and manage Theralink’s observational registry trial, TRACE
(Theralink Registry to Assess Comprehensive Effectiveness). Perthera will utilize its Precision Oncology
Platform, and serve as a Clinical Research Organization (CRO), to establish and launch the participation of
Oncology practices and hospitals in the observational study throughout the US, implement the TRACE
protocol, and assist in the enrollment of patients. Theralink will also utilize Perthera’s Therapeutic
Intelligence Engine™ to deliver a highly differentiated clinical report for physicians to gain clinical decision
support more effectively from the innovative Theralink assay.
Theralink has established TRACE to determine clinical utility using three indicators: Frequency of
Actionable Data, Therapy Selection based upon the Theralink Assay, and Outcomes. Demonstrating
clinical utility will allow Theralink to apply for a reimbursement code to potentially obtain full
reimbursement from 3rd party payors for patients. In TRACE, the Theralink assay will be assessed alongside
commercially available NGS-based genomic assay results. In addition, all patients enrolled in TRACE will
have access to Perthera’s Precision Medicine Platform and proprietary report.
“Partnering with Perthera, whose Platform has been utilized by over 250 cancer care sites, provides us
with an opportunity to have our Theralink Assay reach thousands of breast cancer patients in the U.S. and
the oncologists who treat them. Further, the expert team at Perthera has the proven ability to deploy
their established Precision Oncology Platform to develop and manage the TRACE program to
comprehensively assess the clinical utility of the Theralink assay and to advance our efforts for
reimbursement from the payor community,” said Mick Ruxin, M.D., President and CEO of Theralink
Technologies, Inc. “Together, we may reveal therapeutic options for oncologists, and in turn, potentially
provide better outcomes for breast cancer patients.”
“We are excited to partner with Theralink and use our Platform to drive the TRACE program as we
galvanize the clinical utility of their unique RPPA assay for patients, physicians and payers. The Program
will also capitalize upon Perthera’s outcomes capture capabilities by integrating the world’s first
phosphoprotein assay within Perthera’s proprietary computational engine with AI to deliver precisely
ranked therapeutic options, proven to advance patient outcomes. Initially targeting those who suffer from
breast cancer, and expanding the Program to additional cancer types, this unique combination of RPPA
technology, medicine, science and big data may help dramatically improve outcomes for patients. We
look forward to advancing our integrated partnership and driving Theralink’s innovative testing across the
nation,” said Gary Gregory, CEO of Perthera.
About the RPPA phosphoprotein and protein panel LDT
The RPPA phosphoprotein and protein panel LDT is a custom-built RPPA-based test that measures the
functional activation state of more than thirty proteins that are targets of oncology therapeutics. The LDT
is intended to provide insights as to which therapeutics may be likely to generate the greatest clinical
benefit for a patient’s specific cancer profile and to potentially reveal therapeutics that may be unlikely
to yield clinical benefit. The RPPA phosphoprotein and protein panel LDT has been developed and its
performance characteristics determined by Theralink, the CLIA-certified laboratory performing the assay.
The Theralink assay has not been cleared or approved by the US Food and Drug Administration.
About Perthera
Perthera is one of the leading Precision Oncology Companies advancing cancer care through our Precision
Medicine Platform. Our innovative technology matches cancer patients with precisely ranked therapeutic
recommendations and has been utilized across 250+ US healthcare sites and over 10% of US Oncologists.
We have developed a turnkey, Precision Oncology Platform with an AI-driven Intelligence Engine, which
has been clinically proven to significantly extend cancer patients’ Overall and Progression-Free Survival
rates. Perthera empowers hospitals and physicians to deliver Best-In-Class Cancer Care that may improve
patient outcomes and save lives without altering their current clinical practices, patient flow or lab
preferences. The Perthera Platform allows for the capture, structure and curation of comprehensive Real-
World-Data which delivers significant value to physicians, hospitals, Labs, CROs and Biopharma
organizations.
For more information, visit Perthera.com.
Follow Perthera on Twitter, LinkedIn, and Facebook.
About Theralink Technologies, Inc.
Theralink® Technologies is a proteomics-based, molecular profiling and precision medicine company with
a CLIA-certified laboratory located in Golden, Colorado. Through its unique and patented phosphoprotein
and protein biomarker platform and LDTs, Theralink’s technology targets multiple areas of oncology and
drug development. Theralink provides precision oncology data through its powerful Theralink® Reverse
Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in
identifying likely responders and non-responders to both FDA-approved and investigational drug
treatments. Theralink intends to help improve cancer outcomes for patients, potentially revealing
therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-
genomics approach to molecular profiling that directly measures drug target levels and activity. For more
information, please visit www.theralink.com.
Contact Information
Theralink Technologies, Inc.
KCSA Strategic Communications
Valter Pinto, Managing Director
212.896.1254
valter@kcsa.com
Forward-Looking Statements
Certain statements contained in this press release are “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including, without limitation, anything relating or
referring to future financial results, patient enrollment and plans for future business development
activities, and are thus prospective. Forward-looking statements are inherently subject to risks and
uncertainties some of which cannot be predicted or quantified based on current expectations. Such risks
and uncertainties include, without limitation, the risks and uncertainties set forth from time to time in
reports filed by Theralink Technologies with the Securities and Exchange Commission. We have based
these forward-looking statements largely on our current expectations and projections about future events
and financial trends affecting the financial condition of our business and although the company believes
that the expectations reflected in such forward-looking statements are reasonable, it can give no
assurance that such expectations will prove to have been correct. Consequently, future events and actual
results could differ materially from those set forth in, contemplated by, or underlying the forward the
forward-looking statements contained herein. The company undertakes no obligation to publicly release
statements made to reflect events or circumstances after the date hereof.
